Resilient Bristol Myers Squibb stock trades near $65 as investors digest strong earnings and guidance
Published on 08/18/2026 at 15:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb Inc. (US0897961004) stock closed at $64.72 on August 17, 2026, gaining 1.39% in the latest New York Stock Exchange session as investors continued to respond to a strong recent earnings report and full-year 2026 guidance.
Per a recent quote snapshot as of August 17, 2026, the shares finished regular trading at $64.715, up $0.885 on the day, marking a 20.0% advance from a prior reference level that reflects the stock’s recovery over recent months.
For investors, the combination of a clear earnings beat, raised expectations for 2026 earnings per share and sustained institutional interest is shaping the current narrative around Bristol Myers Squibb stock.
Latest trading levels and market context
Market data compiled in a dedicated overview shows Bristol Myers Squibb closing at $64.71 on August 17, 2026, with the same source highlighting that the stock has increased 20.0% since a previous baseline, underscoring renewed momentum in the large-cap biopharmaceutical name. MarketBeat stock overview for Bristol Myers Squibb
An extended-hours update from the same data set indicates the shares trading at $64.94 in pre-market activity on August 18, 2026, suggesting only a modest adjustment from the prior close as investors digest recent news rather than driving a sharp move.
Additional quote information from a real-time price page reports a closing level of $64.715 for Bristol Myers Squibb on August 17, 2026, with the intraday gain of 1.39% reflecting a constructive reaction to the latest fundamental developments. TradingKey quote for Bristol Myers Squibb
Earnings beat and FY 2026 guidance
The recent earnings report is a key driver behind the share price strength. A detailed quarterly summary states that Bristol Myers Squibb last announced its quarterly results on July 30, 2026, delivering earnings per share (EPS) of $2.04 versus a consensus estimate of $1.60, a positive surprise of $0.44 per share.
In the same quarter, the company generated revenue of $12.97 billion, ahead of a consensus forecast of $11.74 billion, meaning sales exceeded expectations by $1.23 billion.
The earnings overview further notes that Bristol Myers Squibb’s revenue for the quarter increased 5.7% year over year, while EPS in the same period of the prior year stood at $1.46, highlighting solid progress in profitability and top-line expansion. MarketBeat earnings detail for Bristol Myers Squibb
For the full fiscal year 2026, Bristol Myers Squibb has set guidance for EPS in a range of $6.75 to $7.00, according to the same report, with sell-side analysts collectively projecting $6.95 in EPS for the current year.
This guidance range implies that, if achieved, earnings per share would be more than three times the latest quarterly result annualized, and the consensus forecast sitting close to the midpoint of the company’s range suggests that analysts broadly endorse management’s outlook.
The report also highlights robust profitability metrics, including a return on equity of 66.90% and a net margin of 18.87% for the recent quarter, underlining the company’s ability to convert its biopharma portfolio into cash-generative growth.
Dividend investors will note that Bristol Myers Squibb recently paid a quarterly dividend of $0.63 per share, with the payment made on August 3, 2026, to shareholders of record as of July 2, 2026.
On an annualized basis, this dividend corresponds to $2.52 per share and a yield of 3.9% when measured against the recent share price levels around $64 to $65, offering an income component alongside the earnings and growth story.
Institutional flows and analyst consensus
Institutional activity has been supportive. One portfolio update describing a position increase indicates that an asset manager recently raised its stock holdings in Bristol Myers Squibb, with the filing commentary noting that the company currently carries an average rating of moderate buy and a consensus price target of $66.06.
A separate alert on institutional flows provides similar data, repeating that the stock’s consensus target stands at $66.06 with a moderate-buy stance among covering analysts, reinforcing that the market’s central scenario sees modest upside from the latest close. MarketBeat institutional purchase alert for Bristol Myers Squibb
Compared with the August 17, 2026, closing price of $64.71, the $66.06 consensus target represents a potential gain of roughly 2.1%, a relatively measured upside that aligns with the stock’s recent shift from undervalued territory toward what many see as fair valuation.
Another real-time data page examining holdings reports that, as of the first quarter of 2026, institutional investors collectively owned a substantial majority of Bristol Myers Squibb’s shares, reflecting strong engagement from large investors and long-term capital.
For individual investors, the presence of a moderate-buy consensus, visible institutional buying and a clearly defined price target range provides a framework for understanding how the broader market is valuing the company’s pipeline, portfolio and cash flows at current levels.
Chart levels and performance signals
While the latest focus is on earnings and guidance, the technical backdrop is also constructive. The same market-data overview notes a 50-day moving average price of $59.75 and a 200-day moving average price of $59.06 for Bristol Myers Squibb as of the recent data release, implying that the current price around $64.71 stands more than $4.9 above both key moving averages.
This positioning suggests that the stock has broken out of the trading range that prevailed earlier in 2026 and is now consolidating in a higher band, supported by fundamental improvements and market confidence.
On a broader performance basis, an exchange-focused profile indicates that Bristol Myers Squibb shares on a US venue recently showed a 19.83% increase year to date, confirming that the stock has delivered a double-digit return in 2026 compared with levels at the start of the year. MarketScreener performance overview for Bristol Myers Squibb
Separate data from a European trading venue for the same underlying company reports a real-time price of 56.20 EUR on August 18, 2026, with a five-day change of 0.66% and a year-to-date movement of minus 0.66%, illustrating how currency and listing differences can lead to somewhat distinct performance patterns even when the underlying issuer is identical.
For US retail investors focused on the New York Stock Exchange listing in USD, the key takeaway is that Bristol Myers Squibb stock is currently trading solidly above its medium- and long-term moving averages while offering a mid-single-digit dividend yield and guided earnings growth.
Core biopharma portfolio and representative product
Bristol Myers Squibb is known for a range of prescription medicines across oncology, hematology, cardiovascular and immunology, with its portfolio and pipeline providing the foundation for the earnings and guidance figures highlighted in recent market data.
A representative product from the oncology franchise is Opdivo, a programmed death-1 (PD-1) immune checkpoint inhibitor indicated for several types of cancer, including certain lung, melanoma and kidney cancers.
Opdivo’s contribution to revenue growth and its role in combination regimens with other agents help explain the company’s ability to generate $12.97 billion in quarterly revenue and to forecast EPS of $6.75 to $7.00 for fiscal 2026.
The company’s broader pipeline, which includes both small molecules and biologics across late-stage and earlier clinical programs, offers multiple potential catalysts over the coming years, ranging from label expansions for existing therapies to approvals for new treatments in high-need disease areas.
For investors assessing Bristol Myers Squibb stock, understanding how flagship products such as Opdivo, along with other major brands in cardiovascular and immunology, feed into the revenue and margin trajectory is essential.
Shares and valuation picture
As of the close on August 17, 2026, Bristol Myers Squibb stock traded at $64.72 on the New York Stock Exchange, denominated in USD, following a daily gain of 1.39% and standing around 20.0% above a previously referenced level from earlier in the year.
With guided fiscal 2026 EPS in the range of $6.75 to $7.00 and analysts projecting $6.95 in EPS, the current share price implies a forward price-to-earnings multiple centered on the high single digits, a valuation that many market participants view as balanced between the company’s mature cash-generating products and its pipeline risks.
For US retail investors, the combination of a mid-single-digit dividend yield based on the $2.52 annualized payout, a moderate-buy consensus with a $66.06 target and visible progress in quarterly revenue and EPS provides a structured context for evaluating Bristol Myers Squibb stock’s role in a diversified healthcare portfolio.
Go deeper
Investor Relations
More on Bristol Myers Squibb stock
Flagship cancer therapy
One of Bristol Myers Squibb’s flagship oncology products is Opdivo, a PD-1 immune checkpoint inhibitor used in multiple cancer indications, including certain lung, melanoma and renal cancers, and a key contributor to the firm’s recent revenue growth.
Stock level and income profile
Based on the most recent quote snapshot as of August 17, 2026, 4:00 p.m. ET, Bristol Myers Squibb stock closed at $64.72 on the New York Stock Exchange, with an annualized dividend of $2.52 per share translating into a yield of 3.9% at that price level.
Fact box
Company: Bristol Myers Squibb Inc.
ISIN: US0897961004
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 17, 2026, 4:00 p.m. ET): $64.72 USD
Market cap: data from the cited sources indicates a large-cap valuation for Bristol Myers Squibb, consistent with its role as a major global biopharmaceutical company.
Sector / Industry: Health care / Pharmaceuticals and biotechnology
Index membership: S&P 500
